ライフサイエンスコーパス: alpha-galactosylceramide

1 zing iNKT cell agonist, before they received alpha-galactosylceramide.

2 on with glycolipid Ags, such as the model Ag alpha-galactosylceramide.

3 nfection than the invariant NKT cell agonist alpha-galactosylceramide.

4 avidity than the most potent agonist known, alpha-galactosylceramide.

5 has an almost identical fatty acyl chain as alpha-galactosylceramide.

6 proliferative defect after stimulation with alpha-galactosylceramide.

7 ound using the invariant NKT-specific ligand alpha-galactosylceramide.

8 by coactivation of Valpha14 iNKT cells using alpha-galactosylceramide.

9 a in vivo and in vitro after activation with alpha-galactosylceramide.

10 ighly stimulatory invariant NKT cell agonist alpha-galactosylceramide.

11 n a CD1d-dependent manner in the presence of alpha-galactosylceramide.

12 nisms in intact lymphoid tissues, we studied alpha-galactosylceramide.

13 tivation of natural killer T cells by ligand alpha-galactosylceramide.

14 ain, to achieve high affinity recognition of alpha-galactosylceramide.

15 e alterations after NKT cell activation with alpha-galactosylceramide.

16 e five unique GSLs structurally derived from alpha-galactosylceramide.

17 ens: peptides or proteins and the glycolipid alpha-galactosylceramide.

18 igated following activation with CD1d ligand alpha-galactosylceramide.

19 ed type II NKT cells, which do not recognize alpha-galactosylceramide.

20 ot the prototypical type I NKT cell agonist, alpha-galactosylceramide.

21 by provision of a defined exogenous antigen, alpha-galactosylceramide.

22 without needing the iNKT cell agonist ligand alpha-galactosylceramide.

23 yporesponsive to activation with the antigen alpha-galactosylceramide.

24 stricted T cells cross-reacting against CD1d-alpha-galactosylceramide.

25 Since the discovery in 1995 of alpha-galactosylceramide 1 (alpha-GalCer), also known as

26 out three novel subspecies of sphingolipids, alpha-galactosylceramides, 4,5-dihydroceramides, and 1-d

27 The fyn(-/-) NK T cells respond to alpha-galactosylceramide, a ligand recognized by NK T ce

28 Moreover, administration of alpha-galactosylceramide, a potent activating ligand pre

29 Early treatment of NOD mice with alpha-galactosylceramide, a potent NK T cell activator,

30 In addition, injection of mice with alpha-galactosylceramide, a specific glycolipid agonist

31 The administration of alpha-galactosylceramide, a strong NK T-cell agonist, in

32 Corollarily, treatment of mice with alpha-galactosylceramide--a lipid that activates CD1d-re

33 trate that the downstream effects induced by alpha-galactosylceramide activated NK T cells on NK cell

34 Intravenous injection of alpha-galactosylceramide activated NKT1 cells with vascu

35 rferon-gamma and IL-4 production, while oral alpha-galactosylceramide activated NKT2 cells in the mes

36 Blocking 4-1BBL in alpha-galactosylceramide-activated iNKT-monocyte cocultu

37 d by the addition of either TiterMax Gold or alpha-galactosylceramide adjuvant, though adjuvant reduc

38 d by the addition of either TiterMax Gold or alpha-galactosylceramide adjuvant.

39 antimicrobial immune response suggests that alpha-galactosylceramide administration could have a rol

40 the presence or absence of iNKT-cell agonist alpha-galactosylceramide, after which OTI T-cell priming

41 tation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK

42 iate a rapid reaction to the glycolipid drug alpha-galactosylceramide (alpha GalCer), which triggers

43 recognize CD1d-restricted lipid Ags such as alpha-galactosylceramide (alpha GalCer).

44 nted by the marine sponge-derived glycolipid alpha-galactosylceramide (alpha GalCer).

45 the third compound was the glycosphingolipid alpha-galactosylceramide (alpha-GalCer(Bf)), which is st

46 of iNKT through injection of iNKT activator alpha-galactosylceramide (alpha-GalCer) accelerates CCl(

47 alphabeta T lymphocytes, with use of mucosal alpha-galactosylceramide (alpha-GalCer) administration,

48 ine (alpha-GalPhyt) from which 6"-N-modified alpha-galactosylceramide (alpha-GalCer) analogues can be

49 cell receptor beta-chain repertoire and how alpha-galactosylceramide (alpha-GalCer) analogues induce

50 n vivo activation of V alpha 14 NKT cells by alpha-galactosylceramide (alpha-GalCer) and CD1d potenti

51 erably reduces CD1d-mediated presentation of alpha-galactosylceramide (alpha-galcer) and endogenous a

52 nition against altered glycolipid ligands of alpha-galactosylceramide (alpha-GalCer) and have determi

53 activation of NK T cells with the glycolipid alpha-galactosylceramide (alpha-GalCer) and myelin-react

54 sing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated

55 bsence of cytokine production in response to alpha-galactosylceramide (alpha-GalCer) and reduced iNKT

56 er (NK) T cells reactive with the glycolipid alpha-galactosylceramide (alpha-GalCer) are a distinct l

57 CD1d tetramers loaded with alpha-galactosylceramide (alpha-GalCer) bind selectively

58 ent when the highly potent synthetic antigen alpha-galactosylceramide (alpha-GalCer) binds CD1d.

59 ught that recognition of glycolipids such as alpha-galactosylceramide (alpha-GalCer) by the NKT cell

60 variant NKT (iNKT) cells by the superagonist alpha-galactosylceramide (alpha-GalCer) can protect agai

61 Activation of NKT cells with alpha-galactosylceramide (alpha-GalCer) causes liver inj

62 The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown t

63 To harness innate immunity to fight cancer, alpha-galactosylceramide (alpha-GalCer) has been used to

64 The invariant NKT (iNKT) cell ligand alpha-galactosylceramide (alpha-GalCer) holds great prom

65 Administration of alpha-galactosylceramide (alpha-GalCer) in animals enhan

66 n of NKT cells in response to the NKT ligand alpha-galactosylceramide (alpha-GalCer) in both healthy

67 in the third trimester by administration of alpha-galactosylceramide (alpha-GalCer) induced late PTB

68 e administration of the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) induces long-ter

69 NKT cell activation by alpha-galactosylceramide (alpha-GalCer) inhibits autoimm

70 killer T (iNKT)-cells with the superagonist alpha-galactosylceramide (alpha-GalCer) inhibits the dev

71 e development of AHR after administration of alpha-galactosylceramide (alpha-GalCer) intranasally.

72 alpha-Galactosylceramide (alpha-GalCer) is a glycolipid

73 The glycolipid alpha-galactosylceramide (alpha-GalCer) is a potent and

74 alpha-Galactosylceramide (alpha-GalCer) is a potent NKT

75 alpha-Galactosylceramide (alpha-GalCer) is an iNKT cell-

76 alpha-Galactosylceramide (alpha-GalCer) is the prototypi

77 ough administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosi

78 alpha-chain recognize glycolipid Ags such as alpha-galactosylceramide (alpha-GalCer) presented by the

79 NK T cells recognize glycolipid Ags such as alpha-galactosylceramide (alpha-GalCer) presented by the

80 (alpha)14 NKT cells by the glycosphingolipid alpha-galactosylceramide (alpha-GalCer) protects suscept

81 crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a

82 alpha-Galactosylceramide (alpha-GalCer) represents a new

83 tion of mouse iNKT cells with the glycolipid alpha-galactosylceramide (alpha-GalCer) results in the a

84 -cells activated with the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) stimulate a wide

85 eveloping a tumor cell vaccine incorporating alpha-galactosylceramide (alpha-GalCer) that targets the

86 port that the addition of agonist glycolipid alpha-galactosylceramide (alpha-GalCer) to a fetal thymi

87 man CD1 molecules can present the glycolipid alpha-galactosylceramide (alpha-GalCer) to NK T cells fr

88 Alpha-galactosylceramide (alpha-GalCer) was the only gly

89 bamoyl]cholesterol (DC-Chol) with or without alpha-galactosylceramide (alpha-GalCer) were produced by

90 HBV transgenic mice by a single injection of alpha-galactosylceramide (alpha-GalCer), a glycolipid an

91 Alpha-Galactosylceramide (alpha-Galcer), a specific agon

92 alpha-Galactosylceramide (alpha-GalCer), a specific liga

93 e show that a combination of vorinostat with alpha-galactosylceramide (alpha-GalCer), an IFN-gamma-in

94 patitis induced by concanavalin A (ConA) and alpha-galactosylceramide (alpha-GalCer), and hepatotoxin

95 alpha 14(+) TCR to CD1d requires the agonist alpha-galactosylceramide (alpha-GalCer), as opposed to t

96 ller T (NKT) cells by the glycolipid ligand, alpha-galactosylceramide (alpha-GalCer), causes bystande

97 The most powerful iNKT cell antigen is alpha-galactosylceramide (alpha-GalCer), derived from th

98 a synthetic glycolipid agonist of NKT cells, alpha-galactosylceramide (alpha-GalCer), inhibits the de

99 r stages of malaria parasites, a glycolipid, alpha-galactosylceramide (alpha-GalCer), known to select

100 inflammation, the effects of the glycolipid, alpha-galactosylceramide (alpha-GalCer), on dextran sodi

101 The prototypical NKT cell ligand alpha-galactosylceramide (alpha-GalCer), originally isol

102 s, such as the marine sponge-derived reagent alpha-galactosylceramide (alpha-GalCer), results in the

103 ay exquisite specificity for CD1d presenting alpha-galactosylceramide (alpha-GalCer), the extent of l

104 ll agonist that is significantly weaker than alpha-galactosylceramide (alpha-GalCer), the most potent

105 l receptor (TCR) specific for the lipoglycan alpha-galactosylceramide (alpha-GalCer), which is presen

106 nt natural killer T (NKT) cell superagonist, alpha-galactosylceramide (alpha-GalCer), which stimulate

107 and a newly engineered antibody specific for alpha-galactosylceramide (alpha-GalCer)-human CD1d (hCD1

108 thma, including spontaneous, OVA-induced and alpha-galactosylceramide (alpha-GalCer)-induced AHR.

109 tly, in vivo administration of GD3 inhibited alpha-galactosylceramide (alpha-GalCer)-induced NKT cell

110 sitive human NKT cell clones generated using alpha-galactosylceramide (alpha-GalCer)-loaded CD1d tetr

111 Similar to human NKT cells, alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic

112 Remarkably NKT cells activated with alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic

113 We describe an atypical population of CD1d-alpha-galactosylceramide (alpha-GalCer)-reactive human N

114 bition of induction of IFN-gamma and IL-4 by alpha-galactosylceramide (alpha-GalCer)-stimulated liver

115 ognize and respond to glycolipid Ags such as alpha-galactosylceramide (alpha-GalCer).

116 inding of potent, exogenous ligands, such as alpha-galactosylceramide (alpha-GalCer).

117 dendritic cells pulsed with the NKT ligand, alpha-galactosylceramide (alpha-GalCer).

118 presentation of the CD1-restricted antigen, alpha-galactosylceramide (alpha-GalCer).

119 ed with a panel of analogs of the glycolipid alpha-galactosylceramide (alpha-GalCer).

120 with the natural killer T (NKT)-cell agonist alpha-galactosylceramide (alpha-GalCer).

121 leen and lung CD1d-activated iNKT cells with alpha-galactosylceramide (alpha-GalCer).

122 n fruitful using the CD1d-binding glycolipid alpha-galactosylceramide (alpha-GalCer).

123 re liver injury after in vivo challenge with alpha-galactosylceramide (alpha-GalCer).

124 -reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their

125 nistered with the CD1d-binding glycolipid Ag alpha-galactosylceramide (alpha-GC).

126 The phytosphingosine-containing alpha-galactosylceramides (alpha-GalCers), KRN7000 and O

127 ctivation of NKT cells with the CD1d ligand (alpha-galactosylceramide [alpha-GC]) at the time of immu

128 ere measured ex vivo and then incubated with alpha-galactosylceramide (alphaGal) and milk-SL.

129 analyzed presentation of NKT cell activating alpha galactosylceramide (alphaGalCer) analogs that give

130 B6.TCR Jalpha281(-/-) (NKT cell deficient), alpha-galactosylceramide (alphaGalCer) (anergized NKT ce

131 Here we report that alpha-galactosylceramide (alphaGalCer) activated NKT cel

132 ted iNKT cells by cognate glycolipid antigen alpha-galactosylceramide (alphaGalCer) and measured B ce

133 t in situ by studying the adjuvant action of alpha-galactosylceramide (alphaGalCer) in mice.

134 ural killer T cells by using the CD1d ligand alpha-galactosylceramide (alphaGalCer) induces pregnancy

135 The marine sponge glycolipid alpha-galactosylceramide (alphaGalCer) is the proto-typi

136 d of T cell receptor (TCR)-specific reagents alpha-galactosylceramide (alphaGalCer) loaded CD1d-tetra

137 the marine sponge-derived glycosphingolipid alpha-galactosylceramide (alphaGalCer) presented by the

138 owever, strong activation of iNKT cells with alpha-galactosylceramide (alphaGalCer) reportedly induce

139 D1d-restricted invariant NKT (iNKT) cells by alpha-galactosylceramide (alphaGalCer) significantly sup

140 alpha-Galactosylceramide (alphaGalCer) stimulates NKT ce

141 cus pneumoniae, lipopolysaccharide (LPS), or alpha-galactosylceramide (alphaGalCer) to induce pneumon

142 with the natural killer T (NKT) cell ligand, alpha-galactosylceramide (alphaGalCer), ameliorates auto

143 kine responses to CD1d-restricted glycolipid alpha-galactosylceramide (alphaGalCer), anti-CD3 antibod

144 , such as the prototypic NKT cell antagonist alpha-galactosylceramide (alphaGalCer), is currently bei

145 cent tetramers of mouse CD1d1 complexed with alpha-galactosylceramide (alphaGalCer), the antigen reco

146 ar in chemical structure to the well-studied alpha-galactosylceramide (alphaGalCer), with the only ch

147 cells (iNKT) as defined by staining with an alpha-galactosylceramide (alphaGalCer)-loaded CD1d-tetra

148 o selectively stimulate NKT cells in vivo is alpha-galactosylceramide (alphaGalCer).

149 when activated by the CD1d-restricted lipid alpha-galactosylceramide (alphaGalCer).

150 rated lipid variants of the NKT cell antigen alpha-galactosylceramide (alphaGC) exhibit decreased pot

151 r adjuvants monophosphoryl lipid A (MPLA) or alpha-galactosylceramide (alphaGC) failed to elicit resp

152 the invariant NKT (iNKT) immune cell ligand alpha-galactosylceramide (alphaGC) may offer novel tools

153 R-dependent and -independent activation with alpha-galactosylceramide (alphaGC) or IL-18 plus IL-12,

154 Structural variants of alpha-galactosylceramide (alphaGC) that activate invaria

155 Single vaccination with alpha-galactosylceramide (alphaGC)-loaded A20 lymphoma c

156 -administration of a pegylated derivative of alpha-galactosylceramide (alphaGCPEG) with an antigen, e

157 Repeated injection of alpha-galactosylceramide, an agonistic ligand for natura

158 ged bacterial infection by administration of alpha-galactosylceramide, an iNKT cell agonist.

159 since they produce IL-13 upon stimulation by alpha-galactosylceramide, an NK-T cell-specific antigen.

160 e infected with CVB3 and treated with either alpha-galactosylceramide, an NKT cell-specific ligand, o

161 ogical NKT cell activation using a synthetic alpha-galactosylceramide analog (KRN7000) restored local

162 y Vbeta7(+) NKT cells from mice, whereas the alpha-galactosylceramide analog OCH, with a truncated sp

163 tigens that specifically activate NKT cells (alpha-GalactosylCeramide and a Sphingomonas bacterial gl

164 ens, such as an alpha-linked monosaccharide (alpha-galactosylceramide and alpha-galactosyldiacylglyce

165 y with the use of CD1d tetramers loaded with alpha-galactosylceramide and antibodies specific to the

166 ls in these mice, which failed to respond to alpha-galactosylceramide and which therefore were not cl

167 ne production in response to the CD1d ligand alpha-galactosylceramide, and in NKT cell IFN-gamma prod

168 R) alpha-and beta-chains, does not recognize alpha-galactosylceramide, and is referred to as diverse

169 ccommodation made by this TCR in recognizing alpha-galactosylceramide, and it can be assumed that the

170 lls, studies using synthetic pharmacological alpha-galactosylceramides, and the recent discovery of m

171 (iNKT) cells that recognize the prototypical alpha-galactosylceramide antigen, whereas the other majo

172 lthough the CD1d-exposed portions of OCH and alpha-galactosylceramide are identical, structural analy

173 plex with a short-chain synthetic variant of alpha-galactosylceramide at a resolution of 2.2 A.

174 ture of human CD1d in complex with synthetic alpha-galactosylceramide at a resolution of 3.0 A.

175 ivation of iNKT cells by a specific agonist, alpha-galactosylceramide, at the time of infection inhib

176 that failed to respond to the model antigen alpha-galactosylceramide because of an intrinsic defect

177 ut symbiont Bacteroides fragilis can produce alpha-galactosylceramides (BfaGCs), sphingolipids with i

178 n B was also the most efficient in mediating alpha-galactosylceramide binding to recombinant plate-bo

179 The glycolipid alpha-galactosylceramide binds with high affinity to CD1

180 osin B resulted in the lowest recognition of alpha-galactosylceramide by NKT cells.

181 the combination of GH-DT adjuvanted with the alpha-galactosylceramide C34 has the highest enhancement

182 of Cd1d-restricted T cells (NKT cells) with alpha-galactosylceramide caused diminished intestinal co

183 T cells increase, and further activation by alpha-galactosylceramide causes lethal liver injury.

184 a marked decline in the percentage of CD3(+)alpha-galactosylceramide CD1d tetramer(+) cells in the m

185 y a subset of NK T cells, which did not bind alpha-galactosylceramide-CD1d tetramers, was resistant t

186 receptor [TCR] and can be detected using the alpha-galactosylceramide/CD1d tetramer) and type II (exp

187 NKT TCR for CD1d/ threitolceramide than CD1d/alpha-galactosylceramide complexes.

188 Using alpha-galactosylceramide-containing CD1d tetramers to de

189 rated baseline AHR and, when challenged with alpha-GalactosylCeramide, demonstrated even greater AHR.

190 l as a glycosyl acceptor in the synthesis of alpha-galactosylceramide derivatives, was also readily p

191 pha-galactosylceramide-loaded tetramers, and alpha-galactosylceramide did not induce IL-13 secretion.

192 In competition assays, alpha-galactosylceramide did not inhibit Ova presentatio

193 ination with these peptides and the adjuvant alpha-galactosylceramide elicits systemic and mucosal T-

194 ng, activation of NKT cells by lipid agonist alpha-galactosylceramide enhances alternative macrophage

195 ller-like T (NKT) cells with the CD1d ligand alpha-galactosylceramide enhances T-dependent humoral im

196 pregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion.

197 ecreased T-bet expression and in response to alpha-galactosylceramide, had deficient interferon-gamma

198 immature dendritic cells in the presence of alpha-galactosylceramide, IL-2, and IL-15.

199 patic CD1d-restricted NKT cells activated by alpha-galactosylceramide in young but not older dnTGFbet

200 Injection of WT with alpha-galactosylceramide increased removal of senescent

201 NZB x NZW)F(1) mice in vivo or in vitro with alpha-galactosylceramide indicated that the immunoregula

202 ls in the liver and protects from Con A- and alpha-galactosylceramide-induced hepatitis, both of whic

203 of invariant (i)NKT cells with the model Ag alpha-galactosylceramide induces rapid production of mul

204 ed that intrahepatic NK T cells activated by alpha-galactosylceramide inhibit hepatitis B virus repli

205 In wild-type mice, IL-4 levels induced by alpha-galactosylceramide injection could be inhibited by

206 Moreover, repetitive alpha-galactosylceramide injection of mice induced IL-21

207 porating two forms of the NKT cell activator alpha-galactosylceramide into live BCG organisms, and th

208 eceptor is relatively low compared with CD1d-alpha-galactosylceramide (KD of 19-26 muM versus 1 muM).

209 A form of alpha-galactosylceramide, KRN7000, activates CD1d-restri

210 d controls, iNKT cells were enumerated using alpha-galactosylceramide-loaded CD1d tetramers and subse

211 d type I NKT cells, which can be detected by alpha-galactosylceramide-loaded CD1d tetramers, and less

212 These cells bound alpha-galactosylceramide-loaded CD1d tetramers, but exhi

213 atic myeloma with 3 cycles of combination of alpha-galactosylceramide-loaded monocyte-derived dendrit

214 since there was no increase in cells binding alpha-galactosylceramide-loaded tetramers, and alpha-gal

215 y to prime CD8(+) T cells without relying on alpha-galactosylceramide loading.

216 When iNKT cells are activated, whether by alpha-galactosylceramide or during IAV infection, iNKT c

217 intratracheal transfer of OVA-pulsed or OVA-alpha-galactosylceramide (OVA/alphaGalCer)-pulsed bone m

218 nt autoreactivity despite high reactivity to alpha-galactosylceramide presented by CD1d (alpha-GalCer

219 okine production of iNKT cells stimulated by alpha-galactosylceramide presented by CD1d+ Schwann cell

220 Unlike in standard NOD mice, alpha-galactosylceramide pretreatment did not protect th

221 gamma pathway and NKT cells by administering alpha-galactosylceramide-primed bone marrow-derived DCs

222 D4(+) T cells and only moderately stimulated alpha-galactosylceramide-primed invariant NKT cells.

223 ontrast, when NAD is injected into Con A- or alpha-galactosylceramide-primed mice, liver injury is ex

224 ariant NK T (iNKT) cells with the glycolipid alpha-galactosylceramide promotes CD8(+) cytotoxic T cel

225 c activation of NKT cells by the CD1d ligand alpha-galactosylceramide protects susceptible mice from

226 production upon stimulation with anti-CD3 or alpha-galactosylceramide-pulsed APCs.

227 When cocultured with alpha-galactosylceramide-pulsed B cells, CD4(+) and DN i

228 resistant to iNKT cell-dependent lysis than alpha-galactosylceramide-pulsed DCs due to the weaker af

229 roliferated/secreted cytokine in response to alpha-galactosylceramide-pulsed PBMCs; tetramer-staining

230 uding those that are mouse CD1 dependent and alpha-galactosylceramide reactive and those that are not

231 Treatment with alpha-galactosylceramide reduced the bacterial burden in

232 alpha-Galactosylceramide represents a new class of vacci

233 Whereas NKT stimulation by alpha-Galactosylceramide required CD1d expression by den

234 protection has been found to be mediated by alpha-galactosylceramide-responsive type I NKT cells.

235 ing relatively small amounts of incorporated alpha-galactosylceramide retained the ability to robustl

236 nthetic cis-tetracosenoyl sulfatide, but not alpha-galactosylceramide, reverses ongoing chronic and r

237 Mice treated with alpha-galactosylceramide showed significantly reduced my

238 Oral vaccination with alpha-galactosylceramide shows enhanced fecal IgG1 titer

239 Rare CD1d-alpha-galactosylceramide-specific T cells that do not ex

240 are hyperresponsive to anti-CD3, Con A, and alpha-galactosylceramide stimulation and secrete higher

241 oliferation and production of cytokines upon alpha-galactosylceramide stimulation in vitro and in viv

242 The prototypical Ag, alpha-galactosylceramide, strongly activates human and m

243 olipid antigens, including multiple forms of alpha-galactosylceramide that stimulate widely divergent

244 ontrast, following secondary activation with alpha-galactosylceramide, the behavior of iNKT cells is

245 However, repeated treatments with alpha-galactosylceramide, the prototypic glycolipid liga

246 topic sites within these antigens, including alpha-galactosylceramide, the structurally similar alpha

247 diated stimulation with KRN7000, a synthetic alpha-galactosylceramide, they produce a vast amount of

248 mice treated with the iNKT cell superagonist alpha-galactosylceramide through a process involving enh

249 nitrosamine (DEN) to induce liver cancer and alpha-galactosylceramide to activate natural killer T (N

250 nic potential and can present the glycolipid alpha-galactosylceramide to iNKT cells.

251 participation in the CD1d Ag presentation of alpha-galactosylceramide to NK T cells is not necessary.

252 ificant impairment in the ability to present alpha-galactosylceramide to NKT cells.

253 r the binding of an exogenous lipid antigen, alpha-galactosylceramide, to CD1d in the endocytic pathw

254 Importantly, in vivo administration of alpha-galactosylceramide triggered a rapid IL-17 respons

255 ATL146e potently inhibits both anti-CD3 and alpha-galactosylceramide-triggered production of IFN-gam

256 We demonstrate that injection of alpha-galactosylceramide triggers CD70 expression on spl

257 emi-invariant T-cell receptor and react with alpha-galactosylceramide; type II NKT cells use diverse

258 vo expansion with a CD1d-presented lipid Ag (alpha-galactosylceramide) was diminished compared with h

259 C-glycoside analogues of alpha-galactosylceramide were shown to activate both hum

260 ed by studies using the iNKT-specific ligand alpha-galactosylceramide, which causes mild hepatitis in

261 ta-/- mice did not respond to the lipoglycan alpha-galactosylceramide, which is presented by mouse CD

262 nt T cells were stained by tetramers of CD1d/alpha-galactosylceramide, which specifically identify th